BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37616519)

  • 1. Current Treatments in Mantle Cell Lymphoma.
    Avyakta Kallam Md ; Vose JM
    Oncology (Williston Park); 2023 Aug; 37(8):326-333. PubMed ID: 37616519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Directions for Mantle Cell Lymphoma in 2022.
    Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
    Nabrinsky E; Danilov AV; Koller PB
    Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma.
    Lymphoma Research Foundation LRF
    Oncology (Williston Park); 2024 Feb; 38(2):51-67. PubMed ID: 38421601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Jain P; Wang ML
    Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
    Abramson JS; Ghosh N; Smith SM
    Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
    Wallace D; Reagan PM
    Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Eyre TA; Cheah CY; Wang ML
    Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
    Kahl BS; Gordon LI; Dreyling M; Gascoyne RD; Sotomayor EM
    Leuk Lymphoma; 2015; 56(9):2505-11. PubMed ID: 25944379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
    Klener P
    Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-Cell therapy for the management of mantle cell lymphoma.
    Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
    Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.
    Silkenstedt E; Dreyling M
    Hematol Oncol; 2023 Jun; 41 Suppl 1():36-42. PubMed ID: 37294961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
    McCulloch R; Eyre TA; Rule S
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
    Williams ME; Connors JM; Dreyling MH; Gascoyne RD; Kahl BS; Leonard JP; Press OW; Wilson WH
    Leuk Lymphoma; 2011 Jan; 52(1):24-33. PubMed ID: 21133727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dismantling relapsed/refractory mantle cell lymphoma.
    Ryan CE; Kumar A
    Blood Rev; 2024 Jun; ():101221. PubMed ID: 38906740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling and management of mantle cell lymphoma.
    Ruan J
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current trials for frontline therapy of mantle cell lymphoma.
    Steiner RE; Romaguera J; Wang M
    J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.